Annotatedandawaitingreview.Pleasecontactusifyoucanhelpwithreviewing.
CADTK|CAKbeta|CAKB|calcium-dependenttyrosinekinase|celladhesionkinasebeta|FADK2|focaladhesionkinase2|RAFTK|relatedadhesionfocaltyrosinekinase|proline-richtyrosinekinase2
Description:Crystalstructureofkinasedomainofproteintyrosinekinase2beta(PTK2B)
Downloadallstructure-activitydataforthistargetasaCSVfile

Description:Inatime-resolvedfluorescence(TRF)assayusingrecombinantGST-taggedPyk2.
EMDMilliporeKinaseProfilerTMscreen/ReactionBIOLOGyKinaseHotspotSMscreen
Ascreenprofiling158kinaseinhibitors(CalbiochemProteinKinaseInhibitorLibraryIandII,cataloguenumbers539744and539745)fortheirinhibitoryactivityat1Mand10Magainst234humanrecombinantkinasesusingtheEMDMilliporeKinaseProfilerTMservice.

Ascreenprofilingtheinhibitoryactivityof178commerciallyavailablekinaseinhibitorsat0.5Magainstapanelof300recombinantproteinkinasesusingtheReactionBiologyCorporationKinaseHotspotSMplatform.

http://www.millipore.com/techpublications/tech1/pf3036
http://www.reactionbiology.com/webapps/main/pages/kinase.aspx
FAKandPyk2arephosphorylateddownstreamoftheTcellantigenreceptor(TCR)tobringaboutreceptor-specific(e.g.chemokineandintegrinreceptors)Tcelldevelopmentandactivation[5].
PYK2expressionisrelativelyrestrictedwithhighestlevelsinbrainandthehematopoeiticsystem.
Pyk2enzymeisessentialforinflammasomeadaptorproteinASCphosphorylationandoligomerizationnecessaryforNLRP3inflammasomeactivation.
PhysiologicalConsequencesofAlteringGeneExpression
Pyk2(-/-)miceexhibitahighbonemassphenotyperesultingfromincreasedosteogenesisandosteoblastactivity
Pyk2(-/-)micedevelopnormally,butshowdefectsintheirinnumesystem:theyhavenomarginalzoneB-cells,abnormalT-cellindependenttypeIIresponses,andalteredmacrophagemorphology,migrationandsignalinginresponsetocellattachmentorchemokinetreatment.
1.AnastassiADIsT,DeaconSW,DevarajanK,MaH,PetersonJR.(2011)Comprehensiveassayofkinasecatalyticactivityrevealsfeaturesofkinaseinhibitorselectivity.
2.AndersonPC,DeSapioV,TurnerKB,ElmerSP,RoeDC,SchoenigerJS.(2012)Identificationofbindingspecificity-determiningfeaturesinproteinfamilies.
3.BhattacharyaSK,AspnesGE,BagleySW,BoehmM,BrosiusAD,BuckbinderL,ChangJS,DibrinoJ,EngH,FrederickKSetal..(2012)Identificationofnovelseriesofpyrazoleandindole-ureabasedDFG-outPYK2inhibitors.
4.BuckbinderL,CrawfordDT,QiH,KeHZ,OlsonLM,LongKR,BonnettePC,BaumannAP,HamborJE,Grasser3rdWAetal..(2007)Proline-richtyrosinekinase2regulatesosteoProgenitorcellsandboneformation,andoffersananabolictreatmentapproachforosteoporosis.
5.ChapmanNM,HoutmanJC.(2014)FunctionsoftheFAKfamilykinasesinTcells:beyondactincytoskeletalrearrangement.
6.ChungIC,OuYangCN,YuanSN,LiHP,ChenJT,ShiehHR,ChenYJ,OjciusDM,ChuCL,YuJSetal..(2016)Pyk2activatestheNLRP3inflammasomebydirectlyphosphorylatingASCandcontributestoinflammasome-dependentperitonitis.
7.DavisMI,HuntJP,HerrgardS,CiceriP,WodickaLM,PallaresG,HockerM,TreiberDK,ZarrinkarPP.(2011)Comprehensiveanalysisofkinaseinhibitorselectivity.
8.GaoY,DaviesSP,AugustinM,WoodwardA,PatelUA,KovelmanR,HarveyKJ.(2013)Abroadactivityscreeninsupportofachemogenomicmapforkinasesignallingresearchanddrugdiscovery.
9.GuinamardR,OkigakiM,SchlessingerJ,RavetchJV.(2000)AbsenceofmarginalzoneBcellsinPyk-2-deficientmicedefinestheirroleinthehumoralresponse.
10.HanS,MistryA,ChangJS,CunninghamD,GrifforM,BonnettePC,WangH,ChrunykBA,AspnesGE,WalkerDPetal..(2009)Structuralcharacterizationofproline-richtyrosinekinase2(PYK2)revealsaunique(DFG-out)conformationandenablesinhibitordesign.
11.LiuTJ,LaFortuneT,HondaT,OhmoriO,HatakeyamaS,MeyerT,JacksonD,deGrootJ,YungWK.(2007)Inhibitionofbothfocaladhesionkinaseandinsulin-likegrowthfactor-Ireceptorkinasesuppressesgliomaproliferationinvitroandinvivo.
12.OkigakiM,DavisC,FalascaM,HarrochS,FelsenfeldDP,SheetzMP,SchlessingerJ.(2003)Pyk2regulatesmultiplesignalingeventscrucialformacrophagemorphologyandmigration.
13.RobertsWG,UngE,WhalenP,CooperB,HulfordC,AutryC,RichterD,EmersonE,LinJ,KathJetal..(2008)Antitumoractivityandpharmacologyofaselectivefocaladhesionkinaseinhibitor,PF-562,271.
14.WodickaLM,CiceriP,DavisMI,HuntJP,FloydM,SalernoS,HuaXH,FordJM,ArmstrongRC,ZarrinkarPPetal..(2010)Activationstate-dependentbindingofsmallmoleculekinaseinhibitors:structuralinsightsfrombiochemistry.
15.XiaoD,ChengL,LiuX,HuY,XuX,LiuZ,ZhangL,WuW,WangS,ShenYetal..(2012)2,4-DIAMINO-6,7-DIHYDRO-5H-PYRROLO[2,3]PYRIMIDINEDERIVATIVESASFAK/Pyk2INHIBITORS.
Patentnumber:WO2012092880.Assignee:CentaurusBiopharmaCo.,Ltd..Prioritydate:07/01/2011.Publicationdate:12/07/2012.16.YuY,RossSA,HalsethAE,HollenbachPW,HillRJ,GulveEA,BondBR.(2005)RoleofPYK2inthedevelopmentofobesityandinsulinresistance.
Fakfamily:proteintyrosinekinase2beta.Lastmodifiedon23/01/2018.Accessedon18/05/2020.IUPHAR/BPSGuidetoPHARMACOLOGY,http://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=2181.